Drew Ranieri
Stock Analyst at Morgan Stanley
(1.19)
# 3,745
Out of 5,045 analysts
167
Total ratings
44.44%
Success rate
-12.48%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Maintains: Overweight | $75 → $68 | $60.72 | +11.99% | 13 | Jul 15, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.23 | +41.84% | 4 | Mar 5, 2025 | |
| ATEC Alphatec Holdings | Assumes: Equal-Weight | $9.5 → $10 | $16.33 | -38.76% | 10 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $368.98 | +20.60% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $15.15 | +25.41% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $11.81 | +128.62% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $6.35 | +25.98% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $24.94 | -11.79% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $9.86 | -18.86% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $12.63 | +553.21% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $20.14 | +88.68% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $49.99 | +92.04% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.14 | +133.39% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $179.38 | +64.46% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $124.84 | +124.29% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.77 | -26.14% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $19.16 | +265.34% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $530.02 | -43.40% | 6 | Apr 25, 2022 |
Globus Medical
Jul 15, 2025
Maintains: Overweight
Price Target: $75 → $68
Current: $60.72
Upside: +11.99%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.23
Upside: +41.84%
Alphatec Holdings
Dec 2, 2024
Assumes: Equal-Weight
Price Target: $9.5 → $10
Current: $16.33
Upside: -38.76%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $368.98
Upside: +20.60%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $15.15
Upside: +25.41%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $11.81
Upside: +128.62%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $6.35
Upside: +25.98%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $24.94
Upside: -11.79%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $9.86
Upside: -18.86%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $12.63
Upside: +553.21%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $20.14
Upside: +88.68%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $49.99
Upside: +92.04%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.14
Upside: +133.39%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $179.38
Upside: +64.46%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $124.84
Upside: +124.29%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.77
Upside: -26.14%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $19.16
Upside: +265.34%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $530.02
Upside: -43.40%